- Trials with a EudraCT protocol (140)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
140 result(s) found for: Pandemic.
Displaying page 1 of 7.
EudraCT Number: 2009-014770-17 | Sponsor Protocol Number: NVI-255 | Start Date*: 2009-10-09 |
Sponsor Name:Netherlands Vaccine Institute | ||
Full Title: New influenza A (H1N1) disease incidence and immunogenicity of the pandemic influenza A (H1N1) vaccine in healthy adults | ||
Medical condition: influenza A (H1N1) virus infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-005183-15 | Sponsor Protocol Number: CSLCT-CAL-09-60 | Start Date*: 2015-01-09 |
Sponsor Name:CSL Limited | ||
Full Title: A Phase II, Multicentre, Randomised, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children Aged >= 6 Months ... | ||
Medical condition: Influenza, human. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2015-000176-10 | Sponsor Protocol Number: CSLCT-CAL-09-62 | Start Date*: 2015-03-23 |
Sponsor Name:CSL Limited | ||
Full Title: A Phase II, Multicenter, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL’s 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pedi... | ||
Medical condition: Influenza, human. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2020-003904-15 | Sponsor Protocol Number: 20202407 | Start Date*: 2020-08-27 | |||||||||||
Sponsor Name:University of Southern Denmark | |||||||||||||
Full Title: Using BCG vaccine to enhance non-specific protection of senior citizens during the COVID-19 pandemic. A randomized clinical trial. | |||||||||||||
Medical condition: Healthy volunteers, senior citizens of 65 years or older. Immune system activation after BCG vaccination. Acute infections, COVID-19 and self-reported respiratory illness will be monitored. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001051-12 | Sponsor Protocol Number: 11RM013 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Nottingham University Hospitals NHS Trust | |||||||||||||
Full Title: Early low dose steroids for adults admitted to hospital with influenza-like illness during a pandemic: a randomised placebo controlled trial | |||||||||||||
Medical condition: Influenza-like illness | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002340-14 | Sponsor Protocol Number: REMAP-CAP | Start Date*: 2015-09-16 | ||||||||||||||||
Sponsor Name:University Medical Center Utrecht | ||||||||||||||||||
Full Title: Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19) | ||||||||||||||||||
Medical condition: Severe Community Acquired Pneumonia COVID-19 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) IE (Trial now transitioned) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Ongoing) BE (Trial now transitioned) DE (Ongoing) HR (Ongoing) ES (Temporarily Halted) FR (Trial now transitioned) FI (Ongoing) IT (Ongoing) CZ (Trial now transitioned) SI (Ongoing) RO (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012385-31 | Sponsor Protocol Number: V87_17 | Start Date*: 2009-09-01 |
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l. | ||
Full Title: A Phase II, Randomized, Controlled, Double-blind, Multi-center, Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 (Surface Antigen Adj... | ||
Medical condition: Avian influenza | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-005233-11 | Sponsor Protocol Number: MRCH5-1 | Start Date*: 2008-02-21 |
Sponsor Name:University Hospitals Of Leicester NHS Trust, Gwendolen Road | ||
Full Title: A Phase II, Randomized, Partially observer-blind, Single-centre study to Evaluate Safety and Immunogenicity of MF59-adjuvanted or Non-adjuvanted H5N1 Booster Influenza Vaccines in Adults Primed wi... | ||
Medical condition: avian influenza | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-013671-21 | Sponsor Protocol Number: V111_02 | Start Date*: 2009-08-27 |
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l. | ||
Full Title: A Randomized, Single-blind, Dose-Ranging, Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Egg-Derived, Inactivated Novel Swine O... | ||
Medical condition: Pandemic influenza | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) DE (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-000115-28 | Sponsor Protocol Number: 109817 | Start Date*: 2007-07-16 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase II, open, non-randomized study designed to evaluate the reactogenicity and immunogenicity of one or two booster administrations of an influenza pandemic candidate vaccine (GSK1562902A) in a... | ||
Medical condition: Since 1997, avian H5N1 influenza has caused several human infections and high mortality rate in Southeast Asia. Experts warn that the next influenza pandemic is imminent and could be severe. Preven... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-013131-38 | Sponsor Protocol Number: 820903 | Start Date*: 2009-08-13 | |||||||||||
Sponsor Name:Baxter Innovations GmbH | |||||||||||||
Full Title: An open label phase 1/2 study to assess the immunogenicity and safety of two different dose levels of H1N1 pandemic infuenza vaccine in healthy infants, children and adolescents aged 6 months to 17... | |||||||||||||
Medical condition: A/H1N1, Immunogenicity and Safety in Infants, Children and Adolescents, aged 6 months to 17 Years | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017141-58 | Sponsor Protocol Number: V111_06TP_OPERA | Start Date*: 2009-11-19 | |||||||||||
Sponsor Name:OPERA SRL | |||||||||||||
Full Title: An Open-Label Exploratory Clinical Study to Evaluate the Antibody and Cell Mediated Immunity of One Intramuscular Dose of MF59-Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovale... | |||||||||||||
Medical condition: Prophylaxis of A/H1N1sw influenza | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015700-26 | Sponsor Protocol Number: AH1N1-483-09THL | Start Date*: 2009-10-16 | |||||||||||
Sponsor Name:National Institute for Health and Welfare | |||||||||||||
Full Title: Evaluation of a vaccination campaign with A(H1N1)v pandemic vaccines: a prospective cohort study. A(H1N1)v-pandemiarokotuskampanjan vaikutukset | |||||||||||||
Medical condition: Influenza caused by the new A(H1N1)v influenza virus ("swine influenza") | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001888-90 | Sponsor Protocol Number: 20201504 | Start Date*: 2020-04-30 | |||||||||||
Sponsor Name:University of Southern Denmark | |||||||||||||
Full Title: Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic. A randomised controlled multi-center trial. | |||||||||||||
Medical condition: Healthy volunteers, health care workers. Immune system activation after BCG vaccination. Work absenteeism and COVID-19 will be monitored. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016877-14 | Sponsor Protocol Number: H1N1-2009 | Start Date*: 2009-11-04 |
Sponsor Name:COPSAC | ||
Full Title: H1N1v Vaccination of Pregnant Women: A Longitudinal Cohort Study Characterizing Influenza A-H1N1v Vaccination in Pregnant Women | ||
Medical condition: Protection against Influenza A H1N1v disease | ||
Disease: | ||
Population Age: In utero, Preterm newborn infants, Newborns, Infants and toddlers, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-013672-45 | Sponsor Protocol Number: V111_03 | Start Date*: 2009-08-27 |
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l. | ||
Full Title: A Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and non-Adjuvanted Egg-derived, Inactivated Novel Swine... | ||
Medical condition: Pandemic influenza | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) DE (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-001008-49 | Sponsor Protocol Number: NV22155 | Start Date*: 2016-09-30 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche AG | |||||||||||||
Full Title: A randomized, multicenter trial of oseltamivir doses of 75 mg for 5 or 10 days versus 150 mg for 5 or 10 days in influenza patients with pandemic (H1N1) 2009 | |||||||||||||
Medical condition: Influenza | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000165-38 | Sponsor Protocol Number: V87P1E1 | Start Date*: 2007-06-22 | |||||||||||
Sponsor Name:NOVARTIS VACCINES AND DIAGNOSTICS S.R.L. | |||||||||||||
Full Title: A Phase II, Open-label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Booster Dose of FLUAD-H5N1 (Surface Antigen Adjuvanted with MF59C.1) Influenza Vaccine in Non-elderly Adult an... | |||||||||||||
Medical condition: Active immunoprofilaxis against potential pandemic influenza strain. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001281-16 | Sponsor Protocol Number: 107064, 107217 | Start Date*: 2006-05-16 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, observer-blind, randomised study to evaluate the safety and immunogenicity of one and two administrations of pandemic monovalent (H5N1) influenza vaccine (split virus formulation conta... | ||
Medical condition: Immunization against (H5N1) influenza disease in subjects aged 18 years and older. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) DE (Completed) ES (Completed) EE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-001898-32 | Sponsor Protocol Number: V87_30 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Seqirus UK Limited | |||||||||||||
Full Title: A Phase 2, Randomized, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Several Doses of Antigen and MF59 Adjuvant Content in a Monovalent H5N1 Pandemic Influenza Vacc... | |||||||||||||
Medical condition: Prophylaxis for Influenza virus | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.